Brineura Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to lack of alternative cln2 treatments, regulatory orphan drug incentives, improved genetic testing, pediatric neurology specialization, early clinical success of enzyme therapy.

The growth in the forecast period can be attributed to advancements in rare disease diagnostics, increased funding for orphan drugs, expansion of specialized treatment centers, stronger patient advocacy, long term disease management focus. Major trends in the forecast period include growing adoption of enzyme replacement therapies, increased focus on rare pediatric disorders, expansion of orphan drug utilization, improved diagnosis of lysosomal storage disorders, strengthening specialized neurology care.

The rising prevalence of genetic disorders is expected to drive the growth of the Brineura market in the coming years. Genetic disorders are health conditions caused by abnormalities in an individual's DNA, resulting from mutations in one or more genes, chromosomal changes, or a combination of genetic and environmental factors. The increasing prevalence of these conditions is fueled by greater awareness and advances in diagnostic technologies, which enable earlier and more accurate detection of previously undiagnosed cases. Brineura supports the management of genetic disorders by providing targeted enzyme replacement therapy, particularly for patients with CLN2 disease. It helps slow disease progression and improve neurological outcomes, enhancing patients’ quality of life. For example, in July 2025, the National Blood Authority, an Australia-based blood management agency, reported that 2,788 patients were living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Thus, the growing availability of genetic testing is driving the expansion of the Brineura market.

The increasing healthcare expenditure is also expected to support the growth of the Brineura market. Healthcare expenditure encompasses the total financial resources spent on healthcare services, including medical treatments, infrastructure, and programs. The rise in healthcare spending is driven by factors such as an aging population, technological advancements, an increase in chronic diseases, rising costs of medical supplies, and higher expectations for quality care. Healthcare expenditure is particularly important for Brineura accessibility, as its high cost requires substantial funding for rare disease treatments, influencing insurance coverage and affordability. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the Brineura market.

Key companies in the Brineura market are focused on developing and expanding access to advanced enzyme replacement therapies to treat rare genetic disorders, improve patient outcomes, and address unmet medical needs in younger populations. Enzyme replacement therapies provide functional versions of enzymes that patients cannot produce sufficiently due to genetic conditions. For instance, in July 2024, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Brineura (cerliponase alfa) for children under 3 years old with CLN2 disease. This approval extended the treatment to younger pediatric patients and was based on data demonstrating a favorable benefit-risk profile, enabling earlier intervention to slow the progression of this severe neurodegenerative condition.

Major companies operating in the brineura market are BioMarin Pharmaceutical Inc.

North America was the largest region in the brineura market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brineura market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brineura market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the brineura market by increasing costs for imported biologic manufacturing inputs, infusion equipment, and cold chain logistics. These effects are more evident in regions relying on international supply chains such as asia pacific and latin america. Treatment providers face higher operational costs for rare disease therapies. However, tariffs have encouraged localized biologic handling and distribution capabilities. This improves continuity of care for pediatric patients.

The brineura market research report is one of a series of new reports that provides brineura market statistics, including brineura industry global market size, regional shares, competitors with a brineura market share, detailed brineura market segments, market trends and opportunities, and any further data you may need to thrive in the brineura industry. This brineura market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brineura is a biologic enzyme replacement therapy developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2), a rare genetic lysosomal storage disorder affecting the central nervous system. It helps slow the decline of motor function in pediatric patients with CLN2 by replacing the deficient enzyme tripeptidyl peptidase 1 (TPP1).

The primary indications for Brineura are neuronal ceroid lipofuscinosis type 2 (CLN2) and other lysosomal storage disorders. CLN2 is a rare inherited neurodegenerative condition marked by progressive loss of cognitive and motor abilities, leading to severe disability and early death due to lipofuscin accumulation in the brain. Brineura is used across various healthcare settings, including hospitals, clinics, ambulatory care, and home care, and is distributed through channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies.

The brineura market consists of sales of brineura injections, brineura administration kits, dosage adjustments, and special formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.